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Gem/Bu/Mel BEAM Bu/Mel P valueN 89 83 37Age, median (range) 32 (19-61) 36 (17-67) 36 (20-63) 0.7% PIF 64 46 32 0.002% CR1 <6 mo 81 73 86 0.2% prior xRT 27 30 30 0.9% relapse within prior xRT field 12 9 11 0.8% >1 relapses 43 26 22 0.02% bulky tumor at relapse 37 18 22 0.009% B symptoms at relapse 15 14 8 0.6% extranodal disease at relapse 51 30 32 0.01% PET+ at HDC 52 28 27 0.001% PD at HDC 26 6 3 <0.0001The overall and CR rates were: Gem/Bu/Mel: 93% and 81%;
BEAM: 93% and 66%; Bu/Mel: both 64%. Despite its worse prog-
nostic features Gem/Bu/Mel pts had improved EFS (63% v 42% v
38%, P 5 0.002) and OS (85% v 63% v 62%, P 5 0.02) compared
to BEAM or Bu/Mel. Gem/Bu/Mel was superior in both PET-and
PET+ subsets. Cox regressionmodels identified the use of a regimen
other than GemBuMel [risk ratio 2.1 (95% CI, 1.3-3.5), P5 0.002],
PET+ tumors at HDC [RR 1.9 (1.2-3.1), P 5 0.002] and .1 prior
relapse [RR 1.8 (1.1-2.9), P 5 0.01] as independent adverse predic-
tors of EFS.
Conclusions:Despite its markedly worse prognostic features, refrac-
tory HL pts treated with the novel regimen Gem/Bu/Mel show supe-
rior outcome than contemporaneous pts receiving BEAM or Bu/Mel.
A randomized trial of Gem/Bu/Mel vs BEAM is warranted.
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Introduction and Aims:High dose melphalan (HDM) followed by
autologous stem cell transplantation (ASCT) has a central role in the
treatment ofmyeloma.Wehave already shown that patients given the
same dose ofHDMare exposed to a 5 fold variation in total exposure,
as measured by area-under-the-concentration-versus-time curve
(AUC) (1). It may be possible to improve outcomes by modifying
the individual patient dose to optimize their exposure to melphalan.
The aimof this studywas to investigate if exposure toHDMwas a sig-
nificant determinant of outcome in myeloma patients.
Methods:This study included myeloma patients undergoing HDM
at six hematology centres, from 2004-2010. Melphalan concentra-
tions were measured in 6-11 plasma samples collected after a median
dose of 192mg/m2 (range: 136–450 mg). This data was used to de-
velop a population pharmacokinetic model for melphalan (1) and
to determine total exposure to melphalan (AUC) for each patient.
In this pharmacodynamic analysis, we report the relationship be-
tween exposure to various levels of melphalan and clinical outcome.
Transplant toxicities were recorded using the Common Toxicity
Criteria. Factors affecting transplant toxicity and disease outcomes
were analysed by Cox regression analysis.
Results: A total of 115 patients (66 males, 49 females) aged 35-73
years (median 58 years) were studied, with a median follow-up of
3.1 years. Myeloma type was IgG (n 5 72), IgA (n 5 26), biclonal
(n 5 1), Light chain only (n 5 14) and non-secretory (n 5 2). Mel-
phalan AUC ranged from 4.9- 24.6 mg/L.h, median 12.85 mg/L.h.
Risk factors for mucositis of$Grade 3 were higher melphalan expo-
sure (HR1.17, p5 0.03) and higher pre-transplant b2-microglobulin
(HR 4.39, p5 0.007). Patients with AUC above the median were as-
sociated with the following: (1) improved Time to Progression
(TTP), HR 0.56, p\0.02, (2) improved overall survival (OS) at
both 2 years (91% versus 78%) and 4 years (82% versus 55%), HR0.35, (p 5 0.006). Progression free survival was not statistically sig-
nificant, HR 0.64, (p 5 0.08).
Conclusions: Detailed pharmacokinetic data following administra-
tion of HDM confirms that high exposure is associated with more
mucositis, but an improved outcome, as measured by TTP and
OS.These results suggest targeting a higher AUC is warranted in pa-
tients receiving HDM.
(1) Nath CE et al. Br.J.Clin.Pharmacol. 2010; 69: 484 – 497.
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Background: Arrhythmias, especially supraventricular arrhythmias
(SVA), often complicate autologous stem cell transplantation
(ASCT).While easily treatable, they result in prolongation of hospi-
tal stay and increased rate of intensive care admissions. We under-
took this study to determine the incidence and risk factors for
cardiac arrhythmias during ASCT.
Methods:We examined the medical records of 983 patients who un-
derwent ASCT for various hematological malignancies between Aug
2006 andDec 2010.The underlying disease included plasma cell disor-
ders in 573 (58%)patients and lymphomaor leukemia in the remaining.
Results: The median age was 58 years (range; 19-77); 603 (61%)
were male. Overall, 92 (9.4%) patients developed a SVA following
ASCT, at a median of 9 days post transplant (range; 0, 18). Atrial fi-
brillation was most common and was seen in 71 (7%) patients, fol-
lowed by atrial flutter, supraventricular tachycardia and multifocal
tachycardia in 12 (1%), 8 (1%) and 1 (\1%) patients respectively.
The rhythm had normalized in 81 (88%) patients at the time of dis-
missal post transplant, with a median duration of arrhythmia of\1
day (range; \1 to 17 days). We then examined various pre and
peri-transplant clinical and laboratory parameters to identify risk fac-
tors for SVA. In a univariate analysis, older age, presence of supraven-
tricular complexes or AV conduction delays on pre-transplant ECG,
presence of any valvular abnormality, increased atrial size, any prior
history of arrhythmia, or being on a beta blocker or an antiarrhythmic
agent, all increased the risk. In a multivariate analysis, only age. 63
years, presence of supraventricular complexes or AV conduction de-
lays on pre-transplant ECG, and history of any prior arrhythmia in-
creased the risk of arrhythmia during transplant. Among the patients
with age . 63 years, presence of supraventricular complexes or AV
conduction delays on pre-transplant ECG, and history of any prior
arrhythmia, 20%, 26% and 23% respectively developed an arrhyth-
mia compared to 4%, 8% and 8% among those without the risk fac-
tors, respectively (P\ 0.001 for all three comparisons).
Conclusions: Among patients undergoing ASCT, 9% develop sup-
raventricular arrhythmias. The risk is elevated among the older pa-
tients, those with a prior history of arrhythmias, and those with
AV conduction delay or premature supraventricular complexes on
ECG. Identification of patients at a higher risk may allow develop-
ment of specific interventions.ALLOGENEIC TRANSPLANTS15
B CELLS FROM PATIENTS WITH CHRONIC GVHD SIGNAL VIA THE AKT-
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Allogeneic hematopoietic stemcell transplant patients (HSCT)who
develop chronic GVHD (cGVHD) have delayed B cell reconstitution
